Use of Anticoagulant, and Associated Factors of Anticoagulant Refusal Atrial Fibrillation Patients

NCT04062071 | Unknown

• 1 other identifier: version1 last update 30/7/2019
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Atrial fibrillation is a clinically significant cardiac arrhythmia that increases the risk of stroke by 3 to 4 times. Oral anticoagulation has been shown to mitigate stroke risk by two-thirds among patients with AF and is widely recommended in optimizing AF management.Direct oral anticoagulants have also been demonstrated to be superior to warfarin with respect to the risk of fatal bleeding and stroke prevention. However, the previous study finding highlighted a great gap between current guidelines and the clinical management of AF .Nonetheless, the decision for anticoagulant use is not straightforward.It is worth to investigate the updated prevalence of anticoagulant use, the reasons for not receiving anticoagulant, and the factors independently associated with anticoagulant refusal in patients with non-valvular atrial fibrillation.

Conditions

Atrial Fibrillation

Keywords

anticoagulants

Outcome Measures

Primary Outcomes (1)

• The prevalence of anticoagulant use in non-valvular atrial fibrillation patients

  calculate the prevalence of anticoagulant use in non-valvular atrial fibrillation patients

  August 2019 to March 2020

Secondary Outcomes (1)

• the rate of the refusal of anticoagulant use

  August 2019 to March 2020

Interventions

no intervention OTHER

no intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

all of the documented atrial fibrillation patients having regular follow up in GOPC in the study period

You may qualify if:

• diagnosis as atrial fibrillation
• aged ≧18 years
• able to given consent

You may not qualify if:

• Unable/unwillingness to sign informed consent to study
• mechanical heart valve
• moderate-to-severe mitral stenosis
• Transient atrial fibrillation from reversible cause (e.g., during respiratory tract infection or bronchospasm)
• pregnancy

Sponsors & Collaborators

• Prince of Wales Hospital, Shatin, Hong Kong: lead

Study Sites (1)

LIAO, Jiawei

Hong Kong, Hong Kong

Location

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: ECOLOGIC OR COMMUNITY
• Time Perspective: CROSS SECTIONAL
• Target Duration: 2 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: resident

Study Record Dates

• First Submitted: August 16, 2019
• First Posted: August 20, 2019
• Study Start: August 23, 2019
• Primary Completion: March 23, 2020
• Study Completion: March 23, 2020
• Last Updated: August 20, 2019

Record last verified: 2019-08

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)